|Bid||118.86 x 900|
|Ask||119.10 x 800|
|Day's Range||118.89 - 120.66|
|52 Week Range||62.88 - 131.95|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||176.01|
|Earnings Date||Oct 21, 2020 - Oct 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||133.91|
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
You won't find many people who would complain about BioMarin Pharmaceutical's (NASDAQ: BMRN) performance so far this year. Here are the highlights from BioMarin's Q2 update. The company announced a net loss in the second quarter of $29.2 million, or $0.16 per share, based on generally accepted accounting principles (GAAP).
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission such as 10-Q, 10-K and 8-K reports.